PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that regulate lipid and glucose metabolism and cellular differentiation. PPAR-alpha and PPAR-gamma are both expressed in human macrophages where they exert anti-inflammatory effects. The activation of PPAR-alpha may promote foam-cell formation by inducing expression of the macrophage scavenger receptor CD36. This prompted us to investigate the influence of different PPAR-activators on cholesterol metabolism and foam-cell formation of human primary and THP-1 macrophages. Here we show that PPAR-alpha and PPAR-gamma activators do not influence acetylated low density lipoprotein-induced foam-cell formation of human macrophages. In contrast, PPAR-alpha and PPAR-gamma activators induce the expression of the gene encoding ABCA1, a transporter that controls apoAI-mediated cholesterol efflux from macrophages. These effects are likely due to enhanced expression of liver-x-receptor alpha, an oxysterol-activated nuclear receptor which induces ABCA1-promoter transcription. Moreover, PPAR-alpha and PPAR-gamma activators increase apoAI-induced cholesterol efflux from normal macrophages. In contrast, PPAR-alpha or PPAR-gamma activation does not influence cholesterol efflux from macrophages isolated from patients with Tangier disease, which is due to a genetic defect in ABCA1. Here we identify a regulatory role for PPAR-alpha and PPAR-gamma in the first steps of the reverse-cholesterol-transport pathway through the activation of ABCA1-mediated cholesterol efflux in human macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This mechanism is pivotal in controlling intracellular lipid content and serves as a primary “gatekeeper” for reverse cholesterol transport in cells [23].”
From miR-223 accelerates lipid droplets clearance in microglia following spinal cord injury by upregulating ABCA1 (2024) · cites this paper as [23]
In the citing paper
“The activation of PPARα also accelerates reverse cholesterol transport (RCT) via increased expression of ABCA1 and ABCG1 transporters involved in cholesterol efflux from macrophages [29, 40].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [40]
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630 · cited 1×
“, and this led to the suggestion that PPAR-activators may modulate foam-cell formation, a known atherogenic process characterized by cholesteryl-ester-droplet accumulation in the cytoplasm of macrophage”
BackgroundThe peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899 · cited 1×
“Both PPAR-α and PPAR-γ are expressed in fully-differentiated human macrophages where they regulate genes implicated in the inflammatory response, modulate macrophage differentiation and promote TNF-α/IFN-γ–induced apoptosi”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 1×
“We treated these cells with either the PPAR-α ligand Wy14643 or the PPAR-γ ligand rosiglitazone at concentrations of 2–3 times their EC 50 values (Wy14643 EC 50 for human PPAR-αe25 μM and rosiglitazone EC 50 for human PPAR-γe43 nM”
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 1×
“Moreover, PPAR-α activation results in the transcriptional induction of CD36 expression in macrophage”
BackgroundMechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786 · cited 1×
“The stimulatory role of PPAR-α activators on hepatic HDL production and apoAI expression is well-documente”
BackgroundSelf-citationMutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
Brooks-Wilson, A., Marcil, M., Clee, S. M., Zhang, L.-H., Roomp, K., van Dam, M., Yu, L., Brewer, C., Collins, J. A., Molhuizen, H. O. F., et al. (1999) · Nature Genetics · doi:10.1038/11905 · Cited by 1,687
An oxysterol signalling pathway mediated by the nuclear receptor LXRα
Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., & Mangelsdorf, D. J. (1996) · Nature · doi:10.1038/383728a0 · Cited by 1,591 · cited 1×
“We also show that both PPAR-α and PPAR-γ activators induce ABCA1 expression, possibly through their inductive effects on expression of LXR-α, a nuclear receptor activated by oxysterol”
Background
Cited by
(1998) · PubMed · Cited by 2,737
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659
“Two recent studies have suggested that either PPARα (154) or PPARγ (154, 155) activation in macrophages can induce the expression of a cholesterol efflux “pump” known as ABC-A1.”
BackgroundNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Lehrke, M., & Lazar, M. A. (2005) · Cell · doi:10.1016/j.cell.2005.11.026 · Cited by 1,443
“The solution to the paradox of PPARγ increasing lipid uptake in macrophages without increasing atherosclerotic risk has focused on the activation of lipid efflux pathways, such as reverse cholesterol transport, that prevent atherosclerotic lipid accumulation (Chawla et al., 2001a; Chinetti et al., 2001).”
New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport
Lewis, G. F., & Rader, D. J. (2005) · Circulation Research · doi:10.1161/01.res.0000170946.56981.5c · Cited by 1,093
Oliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Peroxisome Proliferator-Activated Receptor Alpha Target Genes
Rakhshandehroo, M., Knoch, B., Müller, M., & Kersten, S. (2010) · PPAR Research · doi:10.1155/2010/612089 · Cited by 1,020
“Presently, it is not clear if this effect of PPARα activation is mediated via LXRα, as was shown previously in macrophages [21].”
BackgroundSorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Synthetic LXR ligand inhibits the development of atherosclerosis in mice
Joseph, S. B., McKilligin, E., Pei, L., Watson, M. A., Collins, A. R., Laffitte, B. A., Chen, M., Noh, G., Goodman, J., Hagger, G. N., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.112059299 · Cited by 947
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Self-citationDiabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Feige, J. N., Gelman, L., Michalik, L., Desvergne, B., & Wahli, W. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2005.12.002 · Cited by 786
PPARs in Obesity-Induced T2DM, Dyslipidaemia and NAFLD
Gross, B., Pawlak, M., Lefebvre, P., & Staels, B. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.135 · Cited by 778
Self-citationThe role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
PPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713
Integrated physiology and systems biology of PPARα
Kersten, S. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.02.002 · Cited by 670
An overview on biological mechanisms of PPARs
KOTA, B., HUANG, T., & ROUFOGALIS, B. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2004.07.012 · Cited by 666
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Self-citationNuclear Receptors and the Control of Metabolism
Francis, G. A., Fayard, E., Picard, F., & Auwerx, J. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142528 · Cited by 636
Liver X Receptor Signaling Pathways in Cardiovascular Disease
Tontonoz, P., & Mangelsdorf, D. J. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0061 · Cited by 633
Yu, S., Matsusue, K., Kashireddy, P., Cao, W.-Q., Yeldandi, V., Yeldandi, A. V., Rao, M. S., Gonzalez, F. J., & Reddy, J. K. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210062200 · Cited by 619
Molecular regulation of HDL metabolism and function: implications for novel therapies
Rader, D. J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci30163 · Cited by 599
The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis
Rader, D. J., Alexander, E. T., Weibel, G. L., Billheimer, J., & Rothblat, G. H. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800088-jlr200 · Cited by 597
Li, A. C., Binder, C. J., Gutierrez, A., Brown, K. K., Plotkin, C. R., Pattison, J. W., Valledor, A. F., Davis, R. A., Willson, T. M., Witztum, J. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci18730 · Cited by 573
Control of Macrophage Activation and Function by PPARs
Chawla, A. (2010) · Circulation Research · doi:10.1161/circresaha.110.216523 · Cited by 531
Macrophage Reverse Cholesterol Transport: Key to the Regression of Atherosclerosis?
Cuchel, M., & Rader, D. J. (2006) · Circulation · doi:10.1161/circulationaha.104.475715 · Cited by 527
Mouse Models for Atherosclerosis and Pharmaceutical Modifiers
Zadelaar, S., Kleemann, R., Verschuren, L., de Vries-Van der Weij, J., van der Hoorn, J., Princen, H. M., & Kooistra, T. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.142570 · Cited by 527
Oram, J. F., & Heinecke, J. W. (2005) · Physiological Reviews · doi:10.1152/physrev.00005.2005 · Cited by 521
A CD36-dependent signaling cascade is necessary for macrophage foam cell formation
Rahaman, S. O., Lennon, D. J., Febbraio, M., Podrez, E. A., Hazen, S. L., & Silverstein, R. L. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.06.007 · Cited by 506
“…such as PPARg, CD36 can participate in the initiation of a transcriptional program that includes upregulation of its own gene as well as those of other critical genes involved in lipid metabolism (Tontonoz et al., 1998; Nagy et al., 1998; Moore et al., 2001; Chinetti et al., 2001; Li et al., 2004).”
BackgroundMarx, N., Duez, H., Fruchart, J.-C., & Staels, B. (2004) · Circulation Research · doi:10.1161/01.res.0000127122.22685.0a · Cited by 501
Self-citationPineda Torra, I., Claudel, T., Duval, C., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0120 · Cited by 487
“pathway (28, 29), modulates glucose and energy ho-”
BackgroundSelf-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
ABCA1: the gatekeeper for eliminating excess tissue cholesterol
Oram, J. F., & Lawn, R. M. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31566-2 · Cited by 480
Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P. J., Shan, L., Gugiu, B., Fox, P. L., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203318200 · Cited by 449
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
“Next to macrophage and DC differentiation and macrophage polarization, PPARg can also directly regulate lipid metabolism in immune cells (37, 87, 92, 97, 98), reminiscent of its role in”
BackgroundMacrophages and lipid metabolism
Remmerie, A., & Scott, C. L. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.01.020 · Cited by 433
Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., & Glass, C. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031789100 · Cited by 429
Barbier, O., Torra, I. P., Duguay, Y., Blanquart, C., Fruchart, J.-C., Glineur, C., & Staels, B. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000015598.86369.04 · Cited by 416
Self-citationBrunham, L. R., Kruit, J. K., Pape, T. D., Timmins, J. M., Reuwer, A. Q., Vasanji, Z., Marsh, B. J., Rodrigues, B., Johnson, J. D., Parks, J. S., et al. (2007) · Nature Medicine · doi:10.1038/nm1546 · Cited by 414
Makowski, L., Brittingham, K. C., Reynolds, J. M., Suttles, J., & Hotamisligil, G. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413788200 · Cited by 410
Thiazolidinediones and PPARγ agonists: time for a reassessment
Cariou, B., Charbonnel, B., & Staels, B. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.03.001 · Cited by 390
Self-citationIncreased Atherosclerosis in Hyperlipidemic Mice With Inactivation of ABCA1 in Macrophages
Aiello, R. J., Brees, D., Bourassa, P.-A., Royer, L., Lindsey, S., Coskran, T., Haghpassand, M., & Francone, O. L. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000014804.35824.da · Cited by 390
Chinetti-Gbaguidi, G., Baron, M., Bouhlel, M. A., Vanhoutte, J., Copin, C., Sebti, Y., Derudas, B., Mayi, T., Bories, G., Tailleux, A., et al. (2011) · Circulation Research · doi:10.1161/circresaha.110.233775 · Cited by 387
Self-citationBAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis
Edwards, P. A., Kast, H. R., & Anisfeld, A. M. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30180-2 · Cited by 385
The liver X receptor gene team: Potential new players in atherosclerosis
Repa, J. J., & Mangelsdorf, D. J. (2002) · Nature Medicine · doi:10.1038/nm1102-1243 · Cited by 388
PPARα: Energy Combustion, Hypolipidemia, Inflammation and Cancer
Pyper, S. R., Viswakarma, N., Yu, S., & Reddy, J. K. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08002 · Cited by 379
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
“Surprisingly, and in sharp contrast to recent findings by using ES cell-derived macrophages (16, 18), troglitazone inhibited ABCA1 expression (whereas other TZDs, such as rosiglitazone, ciglitazone, and pioglitazone, had little effect) and cholesterol efflux in both PPAR -deficient and control macrophages, indicating…”
BackgroundResultInfluentialSelf-citationMicroRNA-mediated regulation of glucose and lipid metabolism
Agbu, P., & Carthew, R. W. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00354-w · Cited by 363
PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis
Li, A. C., & Glass, C. K. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400010-jlr200 · Cited by 357
Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Monsalve, F. A., Pyarasani, R. D., Delgado-Lopez, F., & Moore-Carrasco, R. (2013) · Mediators of Inflammation · doi:10.1155/2013/549627 · Cited by 354
Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues
Van Eck, M., Bos, I. S. T., Kaminski, W. E., Orsó, E., Rothe, G., Twisk, J., Böttcher, A., Van Amersfoort, E. S., Christiansen-Weber, T. A., Fung-Leung, W.-P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092327399 · Cited by 348
Peroxisome Proliferator–Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets
Brown, J. D., & Plutzky, J. (2007) · Circulation · doi:10.1161/circulationaha.104.475673 · Cited by 340
Autoregulation of the Human Liver X Receptor α Promoter
Laffitte, B. A., Joseph, S. B., Walczak, R., Pei, L., Wilpitz, D. C., Collins, J. L., & Tontonoz, P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.22.7558-7568.2001 · Cited by 315
PPARs: transcriptional effectors of fatty acids and their derivatives
Hihi, A. K., Michalik, L., & Wahli, W. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8467-x · Cited by 311
Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes
Yamauchi, T., Waki, H., Kamon, J., Murakami, K., Motojima, K., Komeda, K., Miki, H., Kubota, N., Terauchi, Y., Tsuchida, A., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12864 · Cited by 308
PPARδ is a very low-density lipoprotein sensor in macrophages
Chawla, A., Lee, C.-H., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J., Kang, H., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337331100 · Cited by 305
Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation
Castrillo, A., & Tontonoz, P. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.012103.134432 · Cited by 260
Yoshikawa, T., Ide, T., Shimano, H., Yahagi, N., Amemiya-Kudo, M., Matsuzaka, T., Yatoh, S., Kitamine, T., Okazaki, H., Tamura, Y., et al. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0190 · Cited by 297
Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis
Cao, G., Liang, Y., Broderick, C. L., Oldham, B. A., Beyer, T. P., Schmidt, R. J., Zhang, Y., Stayrook, K. R., Suen, C., Otto, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210208200 · Cited by 299
Chapman, M. J., Le Goff, W., Guerin, M., & Kontush, A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp399 · Cited by 298
Macrophage Differentiation to Foam Cells
Shashkin, P., Dragulev, B., & Ley, K. (2005) · Current Pharmaceutical Design · doi:10.2174/1381612054865064 · Cited by 295
“Some observations show that PPARα and PPARγ do not influence AcLDL-induced FC formation of human macrophages and may just activate ABCA1-mediated cholesterol efflux [151].”
BackgroundPeroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
Regulation of Macrophage Functions by PPAR-α, PPAR-γ, and LXRs in Mice and Men
Rigamonti, E., Chinetti-Gbaguidi, G., & Staels, B. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.158998 · Cited by 293
Self-citationMetabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
Angiotensin II is associated with activation of NF-κB-mediated genes and downregulation of PPARs
Tham, D. M., Martin-McNulty, B., Wang, Y.-X., Wilson, D. W., Vergona, R., Sullivan, M. E., Dole, W., & Rutledge, J. C. (2002) · Physiological Genomics · doi:10.1152/physiolgenomics.00062.2002 · Cited by 277
PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism
Walczak, R., & Tontonoz, P. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30159-0 · Cited by 270
van Raalte, D. H., Li, M., Pritchard, P. H., & Wasan, K. M. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000041444.06122.8d · Cited by 269
“PPARagonists induce ABCA1 expression by an indirect mechanism through the nuclear liver X receptor (LXR)- , which contains a PPRE in its promoter (48).”
BackgroundThe Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages
Vosper, H., Patel, L., Graham, T. L., Khoudoli, G. A., Hill, A., Macphee, C. H., Pinto, I., Smith, S. A., Suckling, K. E., Wolf, C. R., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108482200 · Cited by 268
Chinetti, G., Zawadski, C., Fruchart, J. C., & Staels, B. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.058 · Cited by 264
Self-citationGui, Y., Zheng, H., & Cao, R. Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.845942 · Cited by 258
“Mechanism studies reveals that this effect of PPARα and PPARγ agonists is achieved by promoting the expression of LXRα, and further by increasing the expression of LXRα to promote the expression of ABCA1 (145).”
BackgroundKnouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
HDL Apolipoproteins and ABCA1: Partners in the Removal of Excess Cellular Cholesterol
Oram, J. F. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054662.44688.9a · Cited by 253
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice
Yakar, S., Setser, J., Zhao, H., Stannard, B., Haluzik, M., Glatt, V., Bouxsein, M. L., Kopchick, J. J., & LeRoith, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci17763 · Cited by 252
CD36: Implications in cardiovascular disease
Febbraio, M., & Silverstein, R. L. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.012 · Cited by 247
Regulation of Bile Acid and Cholesterol Metabolism by PPARs
Li, T., & Chiang, J. Y. L. (2009) · PPAR Research · doi:10.1155/2009/501739 · Cited by 241
“Several independent studies evaluating the PPAR effect on macrophage cholesterol efflux have found that both human and mouse ABCA1 are induced upon PPARα and PPARγ activation, suggesting PPAR may have an anti-atherogenic function by regulating cholesterol efflux from macrophages and thus reducing foam cell formation […”
BackgroundPeroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair
Cai, W., Yang, T., Liu, H., Han, L., Zhang, K., Hu, X., Zhang, X., Yin, K.-J., Gao, Y., Bennett, M. V. L., et al. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.002 · Cited by 236
Freed, M. I., Ratner, R., Marcovina, S. M., Kreider, M. M., Biswas, N., Cohen, B. R., & Brunzell, J. D. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02659-0 · Cited by 238
Koldamova, R. P., Lefterov, I. M., Ikonomovic, M. D., Skoko, J., Lefterov, P. I., Isanski, B. A., DeKosky, S. T., & Lazo, J. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300044200 · Cited by 237
Yano, M., Matsumura, T., Senokuchi, T., Ishii, N., Murata, Y., Taketa, K., Motoshima, H., Taguchi, T., Sonoda, K., Kukidome, D., et al. (2007) · Circulation Research · doi:10.1161/01.res.0000268411.49545.9c · Cited by 235
Recent advances in physiological lipoprotein metabolism
Ramasamy, I. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0358 · Cited by 235
Fruchart, J.-C. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.008 · Cited by 233
Self-citationThe rise of antioxidant signaling—The evolution and hormetic actions of Nrf2
Maher, J., & Yamamoto, M. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.01.011 · Cited by 232
Gotto, A. M., & Brinton, E. A. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.061 · Cited by 229
PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice
Tordjman, K., Bernal-Mizrachi, C., Zemany, L., Weng, S., Feng, C., Zhang, F., Leone, T. C., Coleman, T., Kelly, D. P., & Semenkovich, C. F. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11497 · Cited by 229
“Conflicting data (9, 14) address the capacity of PPARs to promote the development of foam cells, essential participants in the atherosclerotic process.”
BackgroundNuclear receptors versus inflammation: mechanisms of transrepression
Pascual, G., & Glass, C. K. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.08.005 · Cited by 228
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Nrf2-regulated PPARγ Expression Is Critical to Protection against Acute Lung Injury in Mice
Cho, H.-Y., Gladwell, W., Wang, X., Chorley, B., Bell, D., Reddy, S. P., & Kleeberger, S. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200907-1047oc · Cited by 226
Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products
Wang, D., Yang, Y., Lei, Y., Tzvetkov, N. T., Liu, X., Yeung, A. W. K., Xu, S., & Atanasov, A. G. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017178 · Cited by 226
“Majdalawieh AF and Ro H-S (2014) The anti-atherogenic properties of sesamin are mediated via improved macrophage cholesterol efflux through PPARg1-LXRa and MAPK signaling.”
BackgroundInfluentialIncreased CD36 protein as a response to defective insulin signaling in macrophages
Liang, C.-P., Han, S., Okamoto, H., Carnemolla, R., Tabas, I., Accili, D., & Tall, A. R. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19528 · Cited by 225
Digby, J. E., Martinez, F., Jefferson, A., Ruparelia, N., Chai, J., Wamil, M., Greaves, D. R., & Choudhury, R. P. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241836 · Cited by 221
Be Fit or Be Sick: Peroxisome Proliferator-Activated Receptors Are Down the Road
Desvergne, B., Michalik, L., & Wahli, W. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0088 · Cited by 222
“PPAR was also shown to promote cholesterol efflux by stimulating ABCA1 expression (95) and to have antiinflammatory functions (96–98).”
BackgroundThe role of fatty acid binding proteins in metabolic syndrome and atherosclerosis
Makowski, L., & Hotamisligil, G. S. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000180166.08196.07 · Cited by 219
Natrajan, M. S., de la Fuente, A. G., Crawford, A. H., Linehan, E., Nuñez, V., Johnson, K. R., Wu, T., Fitzgerald, D. C., Ricote, M., Bielekova, B., et al. (2015) · Brain · doi:10.1093/brain/awv289 · Cited by 218
Transcriptional regulatory networks in lipid metabolism control ABCA1 expression
Schmitz, G., & Langmann, T. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.04.004 · Cited by 219
Watts, G. F., Barrett, P. H. R., Ji, J., Serone, A. P., Chan, D. C., Croft, K. D., Loehrer, F., & Johnson, A. G. (2003) · Diabetes · doi:10.2337/diabetes.52.3.803 · Cited by 219
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
PPARα in atherosclerosis and inflammation
ZANDBERGEN, F., & PLUTZKY, J. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.04.021 · Cited by 214
Nakata, K., Tanaka, Y., Nakano, T., Adachi, T., Tanaka, H., Kaminuma, T., & Ishikawa, T. (2006) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.21.437 · Cited by 215
Metadata
- Authors
- Chinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., Brewer, H. B., Fruchart, J.-C., Clavey, V., & Staels, B.
- Affiliations
- Inserm (FR)
- National Institutes of Health (US)
- Sanofi (France) (FR)
- Corresponding author
- Staels, Bart
- Venue
- Nature Medicine
- Published
- 2001-01
- Volume
- 7
- Issue
- 1
- Pages
- 53-58
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1524478189
- Cited by
- 1,170
- References
- 39
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 31 · 2023: 41 · 2022: 25 · 2021: 28 · 2020: 30 · 2019: 20 · 2018: 29 · 2017: 31 · 2016: 38 · 2015: 33 · 2014: 50 · 2013: 37 · 2012: 38
- FWCI
- 99.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
- Keywords
- PPARα, PPARγ, ABCA1, cholesterol efflux, foam cells, macrophages, reverse cholesterol transport, liver X receptor alpha, apolipoprotein A-I, Tangier disease, acetylated LDL, CD36, THP-1 macrophages
- MeSH terms
- Base Sequence, Biological Transport, Cells, Cultured, Cholesterol, Foam Cells, Humans, Transcription Factors, DNA Primers, Receptors, Cytoplasmic and Nuclear, ATP-Binding Cassette Transporters, ATP Binding Cassette Transporter 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.